Document Type : Original Article

Author

Oncology and Nuclear Medicine Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt

Abstract

Background: Small cell lung cancer (SCLC) is known to be an aggressive cancer with poor prognosis. Prognostic factors are essential for the prediction of treatment outcomes and survival. The present study aimed to evaluate the prognostic value of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) in patients with SCLC.
Method: In this retrospective study, the medical records of 41 patients with SCLC were reviewed; these patients underwent pre-treatment FDG-PET/CT and presented to our institution from January 2012 to December 2017. PET/CT parameters, clinical factors, treatment, and follow-up data were collected and correlated to the overall survival (OS).
Results: The median age of the patients was 61 years, only five of whom (12.2%) were females. Additionally, 29 patients (70.7%) were smokers, 9 (22%) were ex-smokers, and 3 (7.3%) were none-smokers. Among our subjects, 13 (31.7%) had limited stage disease while 28 (68.3%) presented with extensive stage disease. The median pre-treatment maximum standardized uptake value (SUVmax) for the primary tumor was 14.54. The median OS was 18.1 months. Based on univariate analysis, SUVmax, stage, age, and sex were significantly associated with OS. However, smoking status, tumor side, and lobe location had no significant impact on OS. Furthermore, according to multivariate analysis, SUVmax, stage, and age were independent prognostic factors for OS.
Conclusion: SUVmax, age, and tumor stage were found to be significant prognostic factors for OS in patients with SCLC.

Keywords

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination, and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.30476/mejc.2022.94538.1729

  1. van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. 2011;378(9804):1741-55. doi: 10.1016/S0140-6736(11)60165-7.
  2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367-80. doi: 10.1056/NEJMra0802714.
  3. Morabito A, Carillio G, Daniele G, Piccirillo MC, Montanino A, Costanzo R, et al. Treatment of small cell lung cancer. Crit Rev Oncol Hematol. 2014;91(3):257-70. doi: 10.1016/j.critrevonc.2014.03.003.
  4. Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. 2000;89(3):523-33. doi: 10.1002/1097-0142(20000801)89:3<523::aid-cncr7>3.0.co;2-6.
  5. Lassen U, Osterlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH. Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients. J Clin Oncol. 1995;13(5):1215‐ doi: 10.1200/JCO.1995.13.5.1215.
  6. Yip D, Harper PG. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer. 2000;28(3):173-85. doi: 10.1016/s0169-5002(00)00105-7.
  7. Kamel EM, Zwahlen D, Wyss MT, Stumpe KD, von Schulthess GK, Steinert HC. Whole-body (18)F-FDGPET improves the management of patients with small cell lung cancer. J Nucl Med. 2003;44(12):1911-7.
  8. Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA. Positron emission tomography in limited-stage small cell lung cancer: a prospective study. J Clin Oncol. 2004;22(16):3248-54. doi: 10.1200/JCO.2004.11.089.
  9. Vinjamuri M, Craig M, Campbell-Fontaine A, Almubarak M, Gupta N, Rogers JS. Can positron emission tomography be used as a staging tool for small-cell lung cancer? Clin Lung Cancer. 2008;9(1):30-4. doi: 10.3816/CLC.2008.n.005.
  10. Onitilo AA, Engel JM, Demos JM, Mukesh B. Prognostic significance of 18F-fluorodeoxyglucose—positron emission tomography after treatment in patients with limited stage small cell lung cancer. Clin Med Res. 2008;6(2):72-7. doi: 3121/cmr.2008.797.
  11. Ong LT, Dunphy M, Foster A, Woo KM, Zhang Z, Perez CA, et al. Prognostic value of preradiotherapy (18)F-FDG PET/CT volumetrics in limited-stage small-cell lung cancer. Clin Lung Cancer. 2016;17(3):184‐ doi: 10.1016/j.cllc.2015.07.004.
  12. Pandit N, Gonen M, Krug L, Larson SM. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Ear J Nucl Med Mol Imaging. 2003;30(1):78-84. doi: 10.1007/s00259-002-0937-8.
  13. Aktan M, Koc M, Kanyilmaz G, Yavuz BB. Prognostic value of pre-treatment 18F-FDG-PET uptake in small-cell lung cancer. Ann Nucl Med. 2017;31(6):462-8. doi: 10.1007/s12149-017-1178-z.
  14. Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30(6):844-50. doi: 10.1007/s00259-003-1130-4.
  15. Kim JW, Gao P, Dang CV. Effects of hypoxia on tumor metabolism. Cancer Metastasis Rev. 2007;26(2):291-8. doi: 10.1007/s10555-007-9060-4.
  16. Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, et al. Expression of hypoxia inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res. 2001;61(21):7992-8.
  17. Zhu D, Ma T, Niu Z, Zheng J, Han A, Zhao S, et al. Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer. 2011;73(3):332-7. doi: 10.1016/j.lungcan.2011.01.007.
  18. Park SB, Choi JY, Moon SH, Yoo J, Kim H, Ahn YC, et al. Prognostic value of volumetric metabolic parameters measured by [18F]Fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer. Cancer Imaging. 2014;14(1):2. doi: 1186/1470-7330-14-2.
  19. Oh JR, Seo JH, Chong A, Min JJ, Song HC, Kim YC, et al. Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39(6):925-35. doi: 10.1007/s00259-011-2059-7.
  20. Byhardt RW, Hartz A, Libnoch JA, Hansen R, Cox JD. Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL). Int J Radiat Oncol Biol Phys. 1986;12(5):771-7. doi: 10.1016/0360-3016(86)90035-0.
  21. Ludbrook JJ, Truong PT, MacNeil MV, Lesperance M, Webber A, Joe H, et al. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis. Int J Radiat Oncol Biol Phys. 2003;55(5):1321-30. doi: 10.1016/s0360-3016(02)04576-5.
  22. Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. 2000;89(3):523-33. doi: 10.1002/1097-0142(20000801)89:3<523::aid-cncr7>3.0.co;2-6.
  23. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2580-patient South west Oncology Group data base. J Clin Oncol. 1990;8(9):1563-74. doi: 10.1200/JCO.1990.8.9.1563.
  24. Allan SG, Stewart ME, Love S, Cornbleet MA, Smyth JF, Leonard RCF. Prognosis atpresentation of small cell carcinoma of the lung. Eur J Cancer. 1990;26(6):703-5. doi: 10.1016/0277-5379(90)90121-9.